Johnson & Johnson says it will supply the vaccine through a collaboration with Biological E. Limited, the Indian pharma company based in Hyderabad
People queue up for vaccination at a temporary camp set up in a remote village at Morigaon district in Guwahati, on Friday. Pics/AFP
Global healthcare major Johnson & Johnson on Friday said it has applied for Emergency Use Authorization (EUA) of its single-dose vaccine against novel Coronavirus in India. The company, in a statement, said that it will bring the vaccine through a collaboration with Hyderabad-based Biological E. Limited.
ADVERTISEMENT
“Biological E will be an important part of our global supply chain network, helping to supply our Covid-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as Gavi and the COVAX Facility,” it added.
The EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, which demonstrated that company’s single-shot vaccine was 85 per cent effective in preventing severe disease across all regions studied, and showed protection against Covid-19 related hospitalisation and death, beginning 28 days after vaccination, J&J said in the statement.
Daily tally up
India recorded 44,643 new Coronavirus infections and 464 fatalities in a span of 24 hours, according to the Union health ministry data updated on Friday morning. An increase of 3,083 cases was recorded in the active caseload, taking it to 4,14,159.
On Thursday, the ministry had reported 4,11,076 active cases across the country.
Candidates leave an exam centre after appearing in the UP BEd entrance test in Ghaziabad on Friday. Pic/PTI
The national Covid-19 recovery rate was recorded at 97.36 per cent, the data updated at 8 am showed. The daily positivity rate was recorded at 2.72 per cent. It has been less than three per cent for the past 11 days.
Covovax for adults likely by October: SII
Serum Institute of India CEO Adar Poonawalla on Friday said he is hopeful that Covovax, another Covid-19 vaccine being manufactured by his company in India, will be launched in October for adults, and for children by the first quarter of 2022.
Poonawalla met Union home minister Amit Shah in Parliament on Friday. Later, speaking with reporters, he said, “The government is helping us and we are facing no financial crunch. We are thankful to Prime Minister Narendra Modi for all the cooperation and support.”
The SII CEO said he is hopeful that for adults Covovax will be launched in October, depending on DCGI approvals. It will be a two-dose vaccine and the price will be decided at the time of launch, Poonawalla added.
3,18,56,757
Total no. of Coronavirus cases in India so far
4,26,754
Total no. of deaths due to the virus in India so far
4,14,159
Total no. of active cases in India
Aug 51
Day J&J submitted the EUA application to the Indian govt
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
